Long Dang, MD
Medical Oncology · Merritt Island, FLNPI 1528144581
Payments from drug & device makers
Across 107 payments — averaging $137.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$13K
- Johnson & Johnson$212
- Novartis$197
- Merck$182
- Octapharma USA, Inc.$146
- Sirtex Medical Inc$143
- plus $1K from 34 others
What the payments were for
- Food & beverage$2,246100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 9 | $12,510 |
| Johnson & Johnson | 4 | $212 |
| Novartis | 11 | $197 |
| Merck | 7 | $182 |
| Octapharma USA, Inc. | 1 | $146 |
| Sirtex Medical Inc | 1 | $143 |
| AstraZeneca(2 entities) | 8 | $134 |
| Sanofi | 5 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $78 |
| Bristol Myers Squibb | 4 | $73 |
| Amgen | 5 | $71 |
| Seagen Inc. | 4 | $60 |
| Pfizer | 4 | $55 |
| Caris MPI, Inc. | 3 | $53 |
| Brainlab, Inc. | 1 | $53 |
| Boehringer Ingelheim | 3 | $53 |
| GSK | 3 | $48 |
| Taiho Oncology, Inc. | 3 | $48 |
| Tolmar Pharmaceuticals, Inc. | 2 | $42 |
| Incyte Corporation | 2 | $41 |
| Daiichi Sankyo Inc. | 3 | $40 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 2 | $34 |
| Puma Biotechnology, Inc. | 2 | $30 |
| Global Blood Therapeutics, Inc. | 2 | $24 |
| Dendreon Pharmaceuticals LLC | 1 | $23 |
| Myovant Sciences Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Eisai Inc. | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Beigene USA, Inc. | 1 | $20 |
| Myriad Genetic Laboratories, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $16 |
| EMD Serono, Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Morphosys, US Inc. | 1 | $15 |
| Biogen | 1 | $13 |
| Servier Pharmaceuticals LLC | 1 | $12 |
| Heron Therapeutics, Inc. | 1 | $11 |
| Organon | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,700 in reported general payments places this provider in the 45th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 56 | $670,142 |
| PomalystPomalidomide | 27 | $604,730 |
| KisqaliRibociclib Succinate | 26 | $390,129 |
| BrukinsaZanubrutinib | 29 | $263,040 |
| VerzenioAbemaciclib | 17 | $242,856 |
| IbrancePalbociclib | 15 | $235,539 |
| SprycelDasatinib | 12 | $194,970 |
| Lenalidomide | 14 | $186,714 |
| ImbruvicaIbrutinib | 12 | $179,014 |
| LonsurfTrifluridine/Tipiracil Hcl | 12 | $127,082 |
| EliquisApixaban | 91 | $91,304 |
| Abiraterone Acetate | 16 | $79,784 |
| XareltoRivaroxaban | 68 | $55,826 |
| CreonLipase/Protease/Amylase | 22 | $35,349 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 68 | $16,974 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $21 | $799,70039 claims |
| NovartisKisqali | $197 | $390,12926 claims |
| PfizerIbrance, Eliquis | $55 | $326,843106 claims |
| Beigene USA, Inc.Brukinsa | $20 | $263,04029 claims |
| Lilly USA, LLCVerzenio | $16 | $242,85617 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $35 | $179,01412 claims |
| Taiho Oncology, Inc.Lonsurf | $48 | $127,08212 claims |
| Johnson & JohnsonXarelto | $212 | $55,82668 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Merritt Island
- Zeynep ErogluTampa$30.9M
- Manish PatelSarasota$29.7M
- Jad ChahoudTampa$21.8M
- Maen HusseinTavares$18.4M
- Patrick HwuTampa$18M
- Gail WrightHudson$13.8M
- Adil DaudTampa$13.3M
- Lowell HartFort Myers$10.1M
- Judy WangSarasota$9.8M
- Jonathan StrosbergTampa$9.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.